Publications
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Correy GJ, Rachman MM, Togo T, Gahbauer S, Doruk YU, Stevens MGV, Jaishankar P, Kelley B, Goldman B, Schmidt M, Kramer T, Radchenko DS, Moroz YS, Ashworth A, Riley P, Shoichet BK, Renslo AR, Walters WP, Fraser JS. Exploration of structure-activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment linking and active learning. Science advances. 2025. PMID: 40435250
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184
Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, Sridhar H, Tischfield SE, Linkov I, Ceglia N, Zatzman M, Havasov E, Shah NJ, Meng F, Loomis B, Bhanot UK, Redin E, de Stanchina E, Hamard PJ, Koche RP, McPherson A, Quintanal-Villalonga Á, Shah SP, Massagué J, Rudin CM. FOXA2 promotes metastatic competence in small cell lung cancer. Nature communications. 2025. PMID: 40419484
Menzies AM, Long GV, Kohn A, Tawbi H, Webe J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleh JF, di Pietro A, Davies MA. A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. Future oncology (London, England). 2025. PMID: 40418081
Li H, Younger NS, Malik B, Shin HJ, Zhang C, Niknafs Y, Zhao SG, Wilder-Romans K, Pitchiaya S, Han S, Barnard T, Lloyd P, Zhang M, Chesner LN, Calvert M, Egusa EA, Zhu J, Chou J, Das R, Kothari V, Shenoy T, Diolaiti ME, Malik R, Prensner JR, Burlingame A, Ashworth A, Chinnaiyan AM, Feng F, Li H. Identification and Characterization of PLUTO-201, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate Cancer. bioRxiv : the preprint server for biology. 2025. PMID: 40475527
Stinchcombe TE, Fleming GF, Craddock C, Ko AH, O'Reilly EM, Maki RG. Early-Phase Trials in Journal of Clinical Oncology. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40403204
St-Laurent MP, Singh P, McConkey DJ, Lucia MS, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Meeks JJ, Caruso VM, Ward CT, Mazzarella BC, Phillips KG, Bicocca VT, Levin TG, Lerner SP, Black PC. Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. European urology. 2025. PMID: 40404526
Hillege LE, Trepka KR, Guthrie BGH, Fu X, Aarnoutse R, Paymar MR, Olson C, Zhang C, Ortega E, Ramirez L, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Smidt ML, Ziemons J, Turnbaugh PJ. Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio. 2025. PMID: 40391895
Hillege LE, Trepka KR, Guthrie BGH, Fu X, Aarnoutse R, Paymar MR, Olson C, Zhang C, Ortega E, Ramirez L, de Vos-Geelen J, Valkenburg-van Iersel L, van Hellemond IEG, Baars A, Vestjens JHMJ, Penders J, Deutschbauer A, Atreya CE, Kidder WA, Smidt ML, Ziemons J, Turnbaugh PJ. Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio. 2025. PMID: 40391895
Bierer SB, Beck Dallaghan G, Borges NJ, Brondfield S, Fung CC, Huggett KN, Teal CR, Thammasitboon S, Colbert CY. Moving Beyond Simplistic Research Design in Health Professions Education: What a One-Group Pretest-Posttest Design Will Not Prove. MedEdPORTAL : the journal of teaching and learning resources. 2025. PMID: 40395408
Lau G, Sangro B, Cheng AL, Kudo M, Kelley RK, Tak WY, Gasbarrini A, Reig M, Lim HY, Tougeron D, De Toni EN, Tam VC, Mody K, Gong J, Crysler OV, Sukeepaisarnjaroen W, Lipatov O, Morimoto M, Archambeaud I, Burgio V, Phuong LTT, Chao Y, Peron JM, Berres ML, Ko YJ, Ran D, Makowsky M, Negro A, Abou-Alfa GK. Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Hepatology (Baltimore, Md.). 2025. PMID: 40384092
Nguyen RH, Shah PK, Mishra S, Fu J, Reid S, Hawley JE, Hwang C, Singh SRK, Gatson NT, Florez N, Chism D, Serrano OK, Bashir B, Nagaraj G, Mckay RR, Hayes-Lattin B, Koshkin VS, Acoba JD, Zamulko O, Geiger CL, Warner JL, Shah DP, Venepalli NK. Obesity's Disparate Impact on COVID-19 Outcomes in Asian American Patients with Cancer. medRxiv : the preprint server for health sciences. 2025. PMID: 40463536
Luck C, Jacobs KA, Riad J, Macaraig CD, Ponce RKM, Okimoto RA. First Generation Tools for the Modeling of Capicua (CIC) - Family Fusion Oncoprotein-Driven Cancers. bioRxiv : the preprint server for biology. 2025. PMID: 40463157
Corti C, Rugo HS, Tolaney SM. Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 40367401